LSD, psilocybin, DMT +1 moreLSD, psilocybin, DMT, 2C-B show less
Mescaline
Mescaline is a naturally-occurring psychedelic of the phenethylamine class. It is the primary psychoactive compound in peyote cactus and the prototype of the phenethylamine psychedelic family. It activates serotonin receptors in the brain, disrupting the normal filtering of sensory input and producing the visual and emotional shifts characteristic of classical psychedelics.[1]
Mescaline is a naturally-occurring psychedelic of the phenethylamine class. It is the prototype of the phenethylamine psychedelic family, distinguished by its low potency relative to tryptamine and lysergamide psychedelics. Mescaline is a 5-HT₂A receptor agonist, producing its effects by disrupting the brain's default filtering of sensory and cognitive input.[1]
LSD, psilocybin, DMT +1 moreLSD, psilocybin, DMT, 2C-B show less
Arthur Heffter identified mescaline as peyote's active compound in 1897, making it the first psychedelic isolated by Western science.[2] Through the early twentieth century it served as psychiatry's primary research tool for studying altered states; Huxley's The Doors of Perception (1954) then brought it to mainstream attention. International scheduling in 1971 halted clinical research for decades; it remains Schedule I in most countries today, with exemptions for indigenous religious use.[3]
Subjective effects include geometric visual patterns, color enhancement, time alteration, thought acceleration, and a warmth and openness toward others. The experience unfolds slowly over the better part of a day — broader and warmer in feel than LSD, with an interpersonal openness attributed in part to mescaline's unique elevation of oxytocin.[4] Nausea and vomiting during the extended come-up are common and expected.
Mescaline produces no physical dependence and no lethal dose has been established in humans — rapid tolerance after a single use makes compulsive redosing self-limiting.[5][6] The primary risks are psychological — acute anxiety, panic, and potential triggering of psychotic episodes in predisposed individuals — and blood pressure rises consistently, which matters for anyone with cardiovascular conditions.[7] The first controlled trials in humans were published in 2023–2024, establishing core pharmacology, but long-term effects remain uncharacterized.[8][4]
History[edit]
Discovery
In 1897, the German pharmacologist Arthur Heffter identified mescaline as the active compound in peyote cactus (Lophophora williamsii) — the first psychedelic compound isolated by Western science.[2] Ernst Späth achieved the first total synthesis in 1919, enabling laboratory production independent of the cactus.[2][9]
Clinical and Cultural Significance
Through the early twentieth century, mescaline was psychiatry's primary tool for studying altered states. Karl Beringer's 1927 monograph — documenting over sixty experiments — became the foundational clinical text on psychedelic phenomenology.citation needed Huxley's The Doors of Perception (1954) brought it to mainstream attention, and through the 1960s it was used as a psychotherapy adjunct alongside LSD.[3]
Prohibition and Modern Research
Mescaline was placed in Schedule I in 1970 and added to the UN Convention on Psychotropic Substances in 1971, effectively ending clinical research for decades.[3] The first modern controlled trials were published in 2023–2024.[8][4] A 2026 systematic review found the existing psychiatric literature remains limited and highly variable in quality.[10]
Peyote has been used by indigenous peoples of North America for thousands of years in ritual, spiritual, and healing contexts.[9] The Native American Church uses peyote as a central sacrament; its religious use was legally protected by the American Indian Religious Freedom Act of 1978.
Chemistry[edit]
Structural Class
Mescaline belongs to the phenethylamine class — a benzene ring connected to a short ethylamine chain. Three methoxy groups on the ring give it serotonin receptor affinity and define its psychedelic activity.[5]
Its molecular formula is C₁₁H₁₇NO₃ (211.26 g/mol), and it occurs naturally in peyote (Lophophora williamsii), San Pedro (Echinopsis pachanoi), and Peruvian torch (Echinopsis peruviana), alongside other alkaloids that may shape the experience of whole-cactus preparations.[9] Alexander Shulgin's systematic modification of the mescaline scaffold produced the broader 2C-x and DOx families of phenethylamine psychedelics.[11]
Pharmacology[edit]
Mechanism of Action
Mescaline produces its effects by activating serotonin receptors in the brain, disrupting the cortex's normal filtering of sensory input.[8][9] This was confirmed directly in humans: blocking those receptors largely eliminated the subjective experience.[8] Mescaline binds these receptors far less tightly than LSD or psilocin — which is why active doses require hundreds of milligrams rather than micrograms.[5][12]
Pharmacokinetics
After ingestion, mescaline peaks in the bloodstream around 2 hours and has a plasma half-life of roughly 3.5 hours.[8] The experience lasts far longer — between 6 and 14 hours depending on dose — because gut absorption is slow, not because the drug stays bound to receptors.[8][4]
Metabolism
The body breaks mescaline down primarily through monoamine oxidase (MAO) — the same enzyme that metabolizes many neurotransmitters.[13][14] A significant portion leaves the body unchanged in urine.[15] Specific liver enzyme involvement and oral bioavailability have not been studied in humans.
Neuroscience[edit]
Where It Acts
Mescaline activates serotonin receptors on neurons in the outer layers of the neocortex — the brain's main processing hub.[5] This disrupts the brain's normal role as a sensory gatekeeper, allowing information that would ordinarily be filtered out to reach conscious awareness.[8]
Why It Matters
At equivalent doses, mescaline produces an altered state indistinguishable from LSD or psilocybin on validated psychological measures[4] — consistent with a shared mechanism rooted in serotonin receptor activation. Research on the broader psychedelic class suggests these drugs may promote new brain connections through growth factor pathways,[16] though blood markers of this effect do not change acutely with mescaline, LSD, or psilocybin.[4]
- Does mescaline disrupt the brain's default mode network the same way LSD and psilocybin do? No mescaline-specific brain imaging data exist to answer this.
- Does mescaline's unique elevation of plasma oxytocin[4] translate into measurably greater empathy or prosocial behavior compared to other psychedelics?
- What explains the slightly higher rate of adverse effects in the 12–24 hours after a mescaline experience compared to LSD and psilocybin[4]?
Subjective Effects[edit]
Mescaline's defining quality is its pace and breadth. The experience builds slowly over an hour or two, then holds an expansive, daylong alteration of perception and emotion. At lower doses the shift is subtle and navigable; at full doses it becomes all-encompassing, with set and setting shaping the direction over many hours.
At equivalent doses, mescaline produces an altered state qualitatively indistinguishable from LSD or psilocybin on validated measures.[4] What distinguishes it in practice is an interpersonal warmth and openness — attributed in part to mescaline's unique elevation of oxytocin[4] — that sets it apart from LSD's more analytical character and psilocybin's introspective depth.
Arthur Heffter identified mescaline as peyote's psychoactive constituent in 1897, making it the first psychedelic compound isolated by Western science.[2] Decades of psychiatric research and cultural influence followed before international scheduling in the early 1970s halted clinical work.[3] Modern dose-finding trials resumed in the 2020s, and mescaline remains Schedule I in most jurisdictions, with religious exemptions for the Native American Church.
Subjective effects include geometric visual patterns, color enhancement, time alteration, thought acceleration, and empathogenic warmth. The experience unfolds as a slow, expansive arc — a daylong alteration of perception and emotion with an interpersonal openness attributed to mescaline's unique elevation of plasma oxytocin.[4] Nausea, emesis, and anxiety during the extended come-up are characteristic unsought effects.
Mescaline produces no physical dependence, and no lethal dose has been established in humans — rapid tolerance after a single dose makes compulsive redosing self-limiting.[5][6] The primary risks are psychological: acute anxiety, possible psychosis precipitation in predisposed individuals, and dose-dependent blood pressure elevation that compounds in those with pre-existing heart conditions.[7] The first modern controlled trials were published in 2023–2024,[8][4] establishing core pharmacology in humans, though long-term effects and several pharmacokinetic parameters remain uncharacterized.
History[edit]
Discovery
Mescaline was the first psychedelic isolated by Western science. In 1897, the German pharmacologist Arthur Heffter identified it as the primary psychoactive constituent of the peyote cactus (Lophophora williamsii) through systematic self-experiments with purified alkaloid fractions.[2] Ernst Späth achieved total synthesis in 1919,[2][9] establishing its molecular structure and enabling laboratory production independent of cactus material.
Clinical and Cultural Significance
Through the early-to-mid twentieth century, mescaline served as psychiatry's primary tool for studying psychosis-like states in controlled settings. Karl Beringer's 1927 monograph documented over sixty experiments and became the foundational clinical text on psychedelic phenomenology.citation needed Aldous Huxley's The Doors of Perception (1954) brought the compound to mainstream attention, and from the 1940s through the 1960s mescaline and LSD were used as psychotherapy adjuncts for anxiety and alcoholism.[3]
Prohibition and Modern Research
Mescaline was placed in Schedule I under the United States Controlled Substances Act in 1970 and subsequently under the UN Convention on Psychotropic Substances in 1971,[3] effectively suspending clinical research for decades. The first modern dose-finding randomized controlled trials were published by the Liechti group at University Hospital Basel in 2023–2024,[8][4] and Shaw et al. (2026) conducted the first systematic review of mescaline's psychiatric applications, concluding that existing literature remains limited and of highly variable quality.[10]
Peyote has been used by indigenous peoples of North America for thousands of years in ritual, spiritual, and healing contexts.[9] The Native American Church uses peyote as a central sacrament, and its religious use was legally protected by the American Indian Religious Freedom Act of 1978.
Chemistry[edit]
Structural Class
Mescaline (2-(3,4,5-trimethoxyphenyl)ethanamine) belongs to the phenethylamine class — the simplest structural scaffold capable of producing psychedelic effects. The phenethylamine backbone consists of a benzene ring connected to an ethylamine chain; mescaline's activity arises from three methoxy groups at the 3, 4, and 5 positions of the aromatic ring, which confer serotonin receptor affinity.
This trimethoxy substitution pattern is the pharmacophoric core of the mescaline series. Systematic modification of these substituents by Alexander Shulgin generated the broader 2C-x and DOx families of phenethylamine psychedelics.[11]
Unlike the more potent amphetamine-derived psychedelics (the DOx series), mescaline lacks an alpha-methyl group on the ethylamine chain. This makes it susceptible to monoamine oxidase (MAO) metabolism and contributes to its substantially lower potency.[5]
Molecular Properties
| Molecular formula | C₁₁H₁₇NO₃ |
| Molecular weight | 211.26 g/mol |
The molecule is achiral — no stereogenic centers are present, and no active enantiomers require consideration. Mescaline freebase is an oily liquid or low-melting solid. The hydrochloride salt is a white crystalline powder used in all modern clinical research; dose values in the literature refer to the HCl salt mass unless otherwise specified.[8][4]
Natural Occurrence
Mescaline is the primary psychoactive alkaloid of Lophophora williamsii (peyote), Echinopsis pachanoi (San Pedro), and Echinopsis peruviana (Peruvian torch). Peyote contains additional alkaloids including pellotine, anhalonidine, and hordenine,[9] which may modulate the experiential profile of whole-cactus preparations compared with isolated mescaline.
Pharmacology[edit]
Mechanism of Action
Mescaline produces its psychedelic effects primarily through activation of serotonin 5-HT₂A receptors. This was confirmed directly in humans: co-administration of the selective 5-HT₂A blocker ketanserin (40 mg) with 800 mg mescaline reduced subjective effects to levels comparable to 100–200 mg alone.[8] Activation of these receptors on cortical pyramidal neurons triggers intracellular signaling cascades that disrupt normal sensory filtering.[9][5]
Secondary targets include 5-HT₂C and alpha-1 adrenergic receptors.[1][5] Dopamine receptor interaction is weak and not clinically meaningful.[5] Mescaline binds 5-HT₂A far less tightly than LSD or psilocin, which explains why active doses require hundreds of milligrams rather than micrograms. A conformationally restricted structural analog demonstrated substantially higher receptor affinity and potency than mescaline itself, further confirming its relatively modest binding.[12]
Pharmacokinetics
Oral pharmacokinetics were characterized in the first modern dose-finding trial (100–800 mg mescaline HCl, n=16). Peak plasma concentrations occur approximately 2 hours after ingestion, with a plasma half-life of roughly 3.5 hours. Kinetics are dose-proportional across the tested range, with no ceiling on subjective response.[8]
The subjective experience lasts far longer than the plasma half-life would suggest — from 6.4 hours at 100 mg to 14 hours at 800 mg.[8] This discrepancy reflects slow oral absorption rather than extended receptor occupancy, a pattern confirmed by direct pharmacokinetic comparison with LSD.[4]
Metabolism
The primary metabolic pathway is oxidative deamination by monoamine oxidase (MAO), demonstrated in animal tissue[13] and confirmed by MAO inhibitor studies.[14] Secondary pathways include O-demethylation and N-acetylation.[9] A substantial fraction is excreted unchanged in urine.[15]
Specific liver enzyme (CYP) involvement and absolute oral bioavailability have not been formally characterized in humans.
Neuroscience[edit]
Where It Acts
Mescaline activates 5-HT₂A receptors concentrated on the apical dendrites of layer V pyramidal neurons in the neocortex — the canonical cellular site of psychedelic action.[5] Downstream effects, inferred from the serotonergic psychedelic class and mescaline's confirmed 5-HT₂A dependence,[8] include disruption of thalamocortical gating, dissolution of default mode network integrity, increased global functional connectivity, and elevated neural entropy. No mescaline-specific neuroimaging studies have been published.
Why It Matters
Two theoretical frameworks help explain what psychedelics do to the brain. The REBUS model proposes that psychedelics loosen the brain's high-level expectations, allowing raw sensory input to exert greater influence on conscious experience. The entropic brain hypothesis frames this as an increase in the informational richness of neural activity.
The qualitative equivalence of mescaline, LSD, and psilocybin at equipotent doses[4] is consistent with a shared mechanism triggered by 5-HT₂A activation. Class-level evidence supports neuroplasticity through mTOR and BDNF pathway involvement,[16] though acute plasma BDNF levels are unchanged by mescaline, LSD, or psilocybin,[4] suggesting circulating BDNF is not a reliable acute marker of psychedelic-induced neuroplasticity.
- Does mescaline produce the same pattern of default mode network disruption observed with LSD and psilocybin? No mescaline-specific neuroimaging data exist to answer this.
- Does mescaline's unique elevation of plasma oxytocin[4] translate into measurable differences in empathy or prosocial behavior compared to other psychedelics?
- What explains the slightly higher burden of subacute adverse effects (12–24 hours post-dose) relative to LSD and psilocybin[4] — prolonged absorption, secondary receptor targets, or peripheral effects like nausea?
Subjective Effects[edit]
Mescaline's experiential character is defined by expansiveness — a slow-building, daylong alteration of perception and emotion that unfolds gradually rather than arriving in a rush. The extended arc amplifies the influence of set and setting, giving intentional framing and environment hours to shape the trajectory. At lower doses the effects are subtle and manageable; at higher doses the alteration becomes all-encompassing, with nausea during the come-up a near-universal feature.
At equipotent doses, mescaline produces altered states qualitatively indistinguishable from LSD and psilocybin on validated psychometric scales.[4] Its unique elevation of plasma oxytocin[4] may underlie the empathogenic warmth and interpersonal openness traditionally attributed to the compound — a felt quality that distinguishes it from the more analytical character often associated with LSD or the introspective depth of psilocybin.
Effect Grid
At common doses (200–400 mg oral mescaline HCl), the full psychedelic experience emerges: pronounced color enhancement and saturation, geometric visual patterns overlaying surfaces, drifting and morphing of textures and objects, and significant time distortion. Thought connectivity increases dramatically, producing novel associations and insights. Emotional intensification is prominent — music, nature, and interpersonal connections can feel profoundly meaningful. Ego dissolution may occur at the upper end of this range.
Physically, nausea is common during the first 1–2 hours and may progress to vomiting at higher doses within this range. Blood pressure elevation is clinically significant. Jaw tension, temperature dysregulation, and difficulty urinating are typical. Body load is moderate.
Total duration is approximately 9–12 hours. Functional impairment is substantial — the experience demands a full day in a safe, controlled environment. Sleep is difficult for at least 8 hours after ingestion.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Geometry · Visual breathing · Symmetrical texture repetition · Tracers · After-images · Brightness alteration · Environmental patterning · Visual morphing · Holotropic state · Touch enhancement · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Sound sensitivity · Visual melting · Visual acuity enhancement · Synesthesia · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Olfactory enhancement · Visual processing acceleration · Visual magnification · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Object transformations · Visual recursion · Visual scenery slicing · External hallucinations · Environmental orbism / cubism · Object activation · Auditory hallucinations · Visual flipping · Gustatory hallucination · Olfactory hallucination
After-images · Brightness alteration · Environmental patterning · Visual morphing · Holotropic state · Touch enhancement · Auditory distortion · Auditory enhancement · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Sound sensitivity · Visual melting · Visual acuity enhancement · Synesthesia · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Olfactory enhancement · Visual processing acceleration · Visual magnification · Taste enhancement · Tinnitus · Flashbacks · Internal hallucinations · Object transformations · Visual recursion · Visual scenery slicing · External hallucinations · Environmental orbism / cubism · Object activation · Auditory hallucinations · Visual flipping · Gustatory hallucination · Olfactory hallucination
Stimulation · Wakefulness · Appetite suppression · Spontaneous body sensations · Body high · Insomnia · Vomiting · Muscle tension · Dizziness · Dry mouth · Excessive sweating · Heart rate perception changes · Physical fatigue · Restlessness · Tingling / electric sensations · Increased urination · Abnormal heartbeat · Sexual arousal enhancement · Salivation · Bodily heaviness · Bodily pressures · Body schema distortion · Breathing alteration · Dehydration sensation · Motor control impairment · Nystagmus (eye wobbles) · Respiratory stimulation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily lightness · Diarrhea · Headache · Involuntary body movements · Laughter fits · Watery eyes · Motor control enhancement · Bruxism · Kundalini-like energy · Nasal congestion · Pain suppression · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Spontaneous body sensations · Body high · Insomnia · Vomiting · Muscle tension · Dizziness · Dry mouth · Excessive sweating · Heart rate perception changes · Physical fatigue · Restlessness · Tingling / electric sensations · Increased urination · Sexual arousal enhancement · Salivation · Bodily heaviness · Bodily pressures · Body schema distortion · Breathing alteration · Dehydration sensation · Motor control impairment · Nystagmus (eye wobbles) · Respiratory stimulation · Tactile euphoria · Trembling · Vibrations / buzzing · Bodily lightness · Diarrhea · Headache · Involuntary body movements · Laughter fits · Watery eyes · Motor control enhancement · Bruxism · Kundalini-like energy · Nasal congestion · Pain suppression · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Introspection enhancement · Cognitive euphoria · Conceptual thinking · Thought connectivity · Immersion enhancement · Cognitive flexibility · Increased nature relatedness · Openness enhancement · Thought acceleration · Cognitive impairment · Multiple thought streams · Creativity enhancement · Thought loops · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Motivation enhancement · Analysis enhancement · Humor enhancement · Information processing enhancement · Memory suppression · Analysis suppression · Cognitive dysphoria · Memory replays · Language enhancement · Memory enhancement · Thought organization · Language suppression · Motivation suppression · Thought deceleration · Delusions · Amnesia · Delirium
Thought connectivity · Immersion enhancement · Cognitive flexibility · Increased nature relatedness · Openness enhancement · Thought acceleration · Cognitive impairment · Multiple thought streams · Creativity enhancement · Thought loops · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Synchronicity · Thought disorganization · Focus enhancement · Motivation enhancement · Analysis enhancement · Humor enhancement · Information processing enhancement · Memory suppression · Analysis suppression · Cognitive dysphoria · Memory replays · Language enhancement · Memory enhancement · Thought organization · Language suppression · Motivation suppression · Thought deceleration · Amnesia · Delirium
Anxiety · Emotional lability · Simultaneous emotions · Catharsis · Dysphoria · Anxiety suppression · Irritability · Mania
Catharsis · Dysphoria · Anxiety suppression · Irritability
Sociability enhancement · Trust enhancement · Communication enhancement · Flow state · Depersonalization · Communication suppression · Ego inflation · Sociability suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Depersonalization · Communication suppression · Ego inflation · Sociability suppression · Boundary dissolution · Ego dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings
Time cessation
Non-dual awareness · Transpersonal visions · Death-rebirth sequence · Transpersonal memory access · Cessation · Near-death experience · Voidness
Cessation · Near-death experience · Voidness
Recursive awareness
Timeline
First alerts appear as subtle shifts in body awareness and mild mood elevation. A slight warming sensation and gentle nausea may signal absorption.
Effects build gradually as color enhancement, body stimulation, and cognitive loosening emerge. Nausea intensifies during this phase and may peak before or around the transition to full effects. Blood pressure begins rising.
Visual and cognitive effects deepen progressively. Geometric patterning, emotional amplification, and time distortion become prominent. The slow absorption characteristic of mescaline produces a gradual, drawn-out ascent compared to tryptamine psychedelics.
Maximum subjective intensity with full psychedelic effects: vivid visual phenomena, profound thought connectivity, emotional intensification, and possible ego dissolution at higher doses. Cardiovascular effects (elevated BP and HR) are sustained. Nausea typically resolves by this phase.
Effects begin a slow, gentle decline from peak intensity while remaining clearly psychedelic. Visual activity softens, emotional tone often shifts toward warmth and integration. Body load diminishes gradually.
Gradual return toward baseline over several hours. Residual visual enhancement and mild cognitive shifts persist. Emotional processing continues with decreasing intensity.
Residual mood elevation, emotional openness, and mild perceptual brightness may persist for 6-24 hours. Fatigue is common following the long duration of acute effects. Subacute adverse effects (headache, emotional sensitivity) occur slightly more frequently than with LSD or psilocybin.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
Acute Toxicity
No serious adverse events occurred in controlled clinical trials across oral doses of 100–800 mg mescaline HCl.[8] Common adverse effects include raised blood pressure, headache, nausea, and vomiting.[10] Nausea and vomiting become prominent at 800 mg and above.[8]
Heart and Circulation
Mescaline raises blood pressure at oral doses exceeding 100 mg, with similar magnitude of increase across the 200–800 mg range.[8] Heart rate rises in a dose-dependent manner. Anyone with pre-existing blood pressure or heart conditions should treat this as a meaningful risk.
Long-term Toxicity
No liver, kidney, or heart toxicity has been documented in clinical literature. No long-term organ toxicity studies have been published for mescaline specifically.
Psychological Risks
Mescaline can trigger acute anxiety, fear, confusion, and panic — these are part of the expected risk profile of classical psychedelics.[17] It can worsen pre-existing psychotic illness and trigger psychotic episodes in predisposed individuals.[18]
Persistent visual disturbances after the experience has ended are possible.[7] How common this is remains unknown. A large study of over 130,000 adults found no link between lifetime classical psychedelic use and mental health problems or suicidality.[6]
Tolerance & Dependence
Mescaline is non-addictive. Tolerance builds rapidly during and immediately after use — the brain downregulates its serotonin receptors — making repeated dosing self-limiting.[5] No withdrawal or dependence has been documented.[5][6]
Cross-tolerance with LSD, psilocybin, and DMT is well-established.[5] Tolerance resets within approximately 7 days.citation needed
Drug Interactions
Serotonergic Combinations
Alpha-methyltryptamine (αMT) both releases monoamines and blocks monoamine oxidase. Combining it with mescaline creates serious risk of serotonin syndrome — dangerous overheating, rapid heart rate, and seizures.safety citation needed
Tramadol poses serotonin syndrome risk and additionally lowers the seizure threshold.[19]
Chronic SSRI use may substantially blunt or eliminate mescaline's effects by downregulating the serotonin receptors it acts on.[20] Combining SSRIs with mescaline is unpredictable, and serotonin syndrome risk, while likely low, cannot be excluded.
Lithium
Lithium combined with serotonergic psychedelics has caused seizures, tremors, and psychiatric emergencies in case reports involving LSD and psilocybin.[3] No mescaline-specific cases have been published, but the shared mechanism makes this a dangerous interaction.safety citation needed
Cardiovascular Synergism
Combining mescaline with stimulants such as cocaine or amphetamines may produce additive blood pressure and heart rate elevation. No published case reports document these specific combinations with mescaline.
Contraindications
8 knownPsychotic disorders and family history of psychosis are absolute contraindications.[18][3]
Heart conditions and uncontrolled high blood pressure are relative contraindications given mescaline's consistent blood pressure elevation.[8]
Concurrent lithium use is an absolute contraindication based on class-level evidence.[3]
Concurrent MAO inhibitor use is contraindicated — MAO is mescaline's primary metabolic pathway, and inhibiting it would unpredictably increase exposure and risk.
Pregnancy is a contraindication in the absence of reproductive safety data.
Harm Reduction[edit]
Forms & Identification
Mescaline circulates as synthetic powder (HCl or sulfate salts), raw cactus material (dried peyote buttons, San Pedro cuttings), and cactus preparations such as brewed tea or dried powder. Synthetic mescaline is uncommon in unregulated markets, and substances sold as "mescaline" are frequently substituted with other psychedelics.
Reagent testing can rule out several common substitutes but cannot definitively confirm mescaline. Cactus preparations carry inherent dosing uncertainty — alkaloid content varies significantly between specimens and even between buttons from the same plant.
Guidelines
- Test all synthetic material with reagent kits before use
- Start with a low dose, especially with cactus preparations where potency varies
- Clear a full day — experiences at common doses last 10+ hours
- Eat lightly or fast for several hours before ingestion to reduce nausea
- Have ginger tea or anti-nausea remedies on hand
- Arrange a sober companion for the duration, particularly at higher doses
- Keep the environment calm, safe, and free of unexpected intrusions
- Have water, light food, and comfortable clothing accessible
- Do not drive or operate machinery for at least 14 hours after ingestion
Set & Setting
Mescaline's extended duration — often more than 10 hours at common doses — makes environmental planning more important than with shorter-acting psychedelics. A full day should be completely clear of obligations.
A familiar, comfortable space with access to both indoor and outdoor environments is ideal. A sober, trusted companion is strongly recommended, particularly at higher doses. The prolonged come-up — typically 1–2 hours and often accompanied by nausea — can generate anxiety; knowing it is temporary and normal helps.
Aftercare & integration. The day after a mescaline experience is often characterized by physical fatigue and emotional sensitivity. Rest, adequate hydration, and nutritious food support recovery. Journaling within 24–48 hours captures insights that fade quickly.
Integration — making sense of the experience and applying it to daily life — benefits from deliberate reflection. Talking with a trusted friend, therapist, or integration circle can help process challenging material. If distressing thoughts, perceptual changes, or emotional lability persist beyond a few days, seek professional support.
Recovery & Support
Mescaline does not produce physical dependence or withdrawal. Patterns of repeated psychological use are rare but possible, particularly when psychedelics are used to avoid confronting underlying issues rather than to explore them.
If use is becoming a way to escape rather than engage, or if it is interfering with daily functioning, professional guidance is warranted. Harm reduction organizations, psychedelic integration therapists, and peer support communities can provide confidential assistance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult mescaline experiences are psychologically distressing but not medically dangerous. Red flags requiring immediate help include: chest pain, severe headache with visual disturbance (possible blood pressure crisis), self-harm behavior, complete dissociation from reality with inability to respond to verbal reassurance, or seizure.
Immediate steps:
- Move the person to a calm, quiet space
- Speak in a slow, reassuring tone — do not restrain unless there is immediate danger of self-harm
- If conscious, keep them sitting upright and hydrated
- If unconscious, place in the recovery position
- Call emergency services if any red-flag symptoms appear or if the situation does not improve with calm reassurance
What to tell the dispatcher: Name the substance (mescaline), approximate amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
International Framework
Mescaline is classified as a Schedule I substance under the United Nations Convention on Psychotropic Substances (1971), prohibiting manufacture, trade, and possession across signatory states.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Native American Church religious exemption since 1978 (American Indian Religious Freedom Act). Colorado decriminalized natural mescaline (not from peyote) for adults 21+[21] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Dried peyote cactus may be legal to possess; extracted or purified mescaline is controlled[21] |
| Canada | Schedule III (CDSA 2001) | Peyote plant specifically exempted from scheduling[21] |
| Australia | Schedule 9 (Poisons Standard) | Prohibited substance[21] |
| Mexico | Prohibited | Peyote protected as cultural heritage; indigenous and religious use may be de facto tolerated[21] |
| European Union | Varies by member state | Generally Schedule I equivalent, implementing UN 1971 Convention[21] |
Plant vs. Compound Distinction
Several jurisdictions treat the purified alkaloid differently from its plant sources. Canada exempts the peyote plant from scheduling while controlling extracted mescaline. The United Kingdom may permit possession of dried peyote while prohibiting the purified compound. Preparations such as brewed cactus tea fall into a legal grey area that courts, rather than statutes, tend to define.
Legal status varies by jurisdiction and changes over time. This is not legal advice. Verify the current law in your jurisdiction before acting.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · DMT
Toxicity
Acute Toxicity
No serious adverse events occurred in controlled clinical trials across oral doses of 100–800 mg mescaline HCl.[8] Common adverse effects include raised blood pressure, headache, nausea, and vomiting.[10] Nausea and emesis are particularly prominent at 800 mg and above.[8]
Heart and Circulation
Mescaline produces clinically significant blood pressure elevation at oral doses exceeding 100 mg, with similar magnitude of increase across 200–800 mg.[8] Heart rate increases in a dose-dependent manner. These effects warrant caution in anyone with pre-existing blood pressure or heart conditions.
Long-term Toxicity
No liver, kidney, or heart toxicity has been documented in clinical literature. No long-term organ toxicity studies have been published for mescaline specifically.
Psychological Risks
Mescaline is listed among substances associated with hallucinogen-persisting perception disorder (HPPD) — visual disturbances that persist or recur after acute effects have resolved.[7] HPPD remains poorly understood, with no reliable prevalence estimates.
Mescaline can worsen pre-existing psychotic illness and trigger psychotic episodes in predisposed individuals. Historical clinical observations documented symptom exacerbation in patients with latent schizophrenia following intravenous mescaline.[17]
Acute challenging psychological experiences — anxiety, fear, confusion, and difficult emotional states — occur at variable frequency and are part of the expected risk profile of serotonergic psychedelics.[18] A population-level study of 130,152 US adults found no association between lifetime classical psychedelic use and increased rates of mental health problems, suicidality, or psychological distress.[6]
Tolerance & Dependence
Mescaline is non-addictive. Rapid tolerance develops during and immediately after use through 5-HT₂A downregulation.[5] No compulsive use patterns, withdrawal, or dependence have been documented.[5][6]
Cross-tolerance with other serotonergic psychedelics (LSD, psilocybin, DMT) is well-established.[5] Class-level data suggest tolerance resets within approximately 7 days.citation needed
Drug Interactions
Serotonergic Combinations
The most dangerous interactions involve substances that increase serotonin levels or inhibit monoamine oxidase. Alpha-methyltryptamine (αMT), which functions as both a monoamine releaser and an MAO inhibitor, creates risk of severe serotonin syndrome — a potentially lethal combination.safety citation needed Tramadol poses serotonin syndrome risk and additionally lowers the seizure threshold.[19]
Chronic SSRI use downregulates 5-HT₂A receptors and may substantially blunt or eliminate psychedelic effects.[20] The outcome of combining SSRIs with mescaline is unpredictable, and serotonin syndrome risk, while likely low, cannot be excluded.
Lithium
Concurrent use of lithium with serotonergic psychedelics is associated with seizures, tremors, and psychiatric emergencies in case reports involving LSD and psilocybin.[3] No mescaline-specific cases have been published, but the shared mechanism supports classification as a dangerous interaction.safety citation needed
Cardiovascular Synergism
Combining mescaline with other stimulants (cocaine, amphetamines) may produce additive cardiovascular stress through combined elevation of blood pressure and heart rate. No published case reports document these specific combinations with mescaline.
Contraindications
8 knownPsychotic disorders and family history of psychosis are absolute contraindications, supported by historical evidence of psychosis exacerbation.[17][3]
Heart conditions and uncontrolled high blood pressure are relative contraindications given mescaline's consistent blood pressure elevation.[8]
Concurrent lithium use is an absolute contraindication based on class-level evidence.[3]
Concurrent MAO inhibitor use is contraindicated due to serotonin syndrome risk. MAO is mescaline's primary metabolic pathway, so inhibition would increase exposure unpredictably.
Pregnancy is a contraindication in the absence of reproductive safety data.
Harm Reduction[edit]
Forms & Identification
Mescaline circulates as synthetic powder (HCl or sulfate salts), raw cactus material (dried peyote buttons, San Pedro cuttings), and cactus preparations (brewed tea, dried powder). Synthetic mescaline is uncommon in unregulated markets, and substances sold as "mescaline" are frequently substituted with other psychedelics.
Reagent testing cannot distinguish mescaline from all possible substitutes but can rule out several common ones. For cactus preparations, dosing is inherently imprecise due to variable alkaloid content between specimens — two buttons from the same plant may differ substantially in potency.
Guidelines
- Test all synthetic material with reagent kits before use
- Start with a low dose, especially with cactus preparations where potency varies
- Clear a full day — experiences at common doses last 10+ hours
- Eat lightly or fast for several hours before ingestion to reduce nausea
- Have ginger tea or anti-nausea remedies on hand
- Arrange a sober companion for the duration, particularly at higher doses
- Keep the environment calm, safe, and free of unexpected intrusions
- Have water, light food, and comfortable clothing accessible
- Do not drive or operate machinery for at least 14 hours after ingestion
Set & Setting
Mescaline's extended duration — often exceeding 10 hours at common doses — makes environmental planning more important than with shorter-acting psychedelics. A full day should be cleared of obligations. A familiar, comfortable physical space with access to both indoor and outdoor environments is ideal.
The presence of a sober, trusted companion is strongly recommended, particularly at higher doses. The prolonged come-up (1–2 hours), often accompanied by nausea, can generate anxiety; knowing this is a normal and temporary phase helps reduce distress.
Aftercare & integration. The day after a mescaline experience is often characterized by physical fatigue and emotional sensitivity. Rest, adequate hydration, and nutritious food support recovery. Journaling within 24–48 hours captures insights and emotional textures that fade quickly.
Integration — the process of making sense of the experience and applying it to daily life — benefits from deliberate reflection. Talking with a trusted friend, therapist, or integration circle can help process challenging material. If distressing thoughts, perceptual changes, or emotional lability persist beyond a few days, seek professional support.
Recovery & Support
Mescaline does not produce physical dependence or withdrawal. Psychological patterns of repeated use are rare but possible, particularly when psychedelics are used to avoid confronting underlying issues rather than to explore them.
If psychedelic use is becoming a way to escape rather than engage, or if it is interfering with daily functioning, professional guidance is warranted. Harm reduction organizations, psychedelic integration therapists, and peer support communities can provide confidential assistance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult mescaline experiences are psychologically distressing but not medically dangerous. Red flags requiring immediate help include: chest pain, severe headache with visual disturbance (possible blood pressure crisis), self-harm behavior, complete dissociation from reality with inability to respond to verbal reassurance, or seizure.
Immediate steps:
- Move the person to a calm, quiet space
- Speak in a slow, reassuring tone — do not restrain unless there is immediate danger of self-harm
- If conscious, keep them sitting upright and hydrated
- If unconscious, place in the recovery position
- Call emergency services if any red-flag symptoms appear or if the situation does not improve with calm reassurance
What to tell the dispatcher: Name the substance (mescaline), approximate amount and time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
International Framework
Mescaline is classified as a Schedule I substance under the United Nations Convention on Psychotropic Substances (1971), which prohibits manufacture, trade, and possession across signatory states.[3] National implementations vary; several jurisdictions distinguish between the purified compound and its plant sources.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Native American Church religious exemption since 1978 (American Indian Religious Freedom Act). Colorado decriminalized natural mescaline (not from peyote) for adults 21+[21] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Dried peyote cactus may be legal to possess; extracted or purified mescaline is controlled[21] |
| Canada | Schedule III (CDSA 2001) | Peyote plant specifically exempted from scheduling[21] |
| Australia | Schedule 9 (Poisons Standard) | Prohibited substance[21] |
| Mexico | Prohibited | Peyote protected as cultural heritage; indigenous and religious use may be de facto tolerated[21] |
| European Union | Varies by member state | Generally Schedule I equivalent, implementing UN 1971 Convention[21] |
Plant vs. Compound Distinction
A notable feature of mescaline's legal landscape is the differential treatment of the purified alkaloid versus its plant sources. Canada explicitly exempts the peyote plant from scheduling while controlling extracted mescaline. The United Kingdom may permit possession of dried peyote while prohibiting the purified compound.
This distinction creates legal ambiguity around preparations such as brewed cactus material, which contains both scheduled mescaline and unscheduled plant matrix. The legal status of any specific preparation depends on jurisdiction, form, and intent — and may be subject to interpretation by courts rather than clearly defined in statute.
Frequently asked questions
How long does Mescaline last?
Total duration by route of administration — Oral: 6 – 14 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Mescaline?
Psychedex publishes a dosage table for Mescaline on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Mescaline?
The highest-severity documented interactions for Mescaline: MAOIs (Lethal), Buspirone (Dangerous), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Mescaline addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Mescaline: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, psilocybin, DMT, 2C-B. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcNichols DE, Walter H (2021) The History of Psychedelics in Psychiatry — Pharmacopsychiatry doi:10.1055/a-1310-3990
- [3]
- [4] ^abcdefghijLey L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants — Neuropsychopharmacology doi:10.1038/s41386-023-01607-2
- [5]
- [6] ^abcKrebs TS, Johansen PO (2013) Psychedelics and mental health: a population study — PLoS ONE doi:10.1371/journal.pone.0063972
references
- [1]
- [2] ^abcNichols DE, Walter H (2021) The History of Psychedelics in Psychiatry — Pharmacopsychiatry doi:10.1055/a-1310-3990
- [3]
- [4] ^abcdefghijkLey L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants — Neuropsychopharmacology doi:10.1038/s41386-023-01607-2
- [5]
- [6] ^abcKrebs TS, Johansen PO (2013) Psychedelics and mental health: a population study — PLoS ONE doi:10.1371/journal.pone.0063972